ArticleDiabetologia2007
Liver X receptor antagonist reduces lipid formation and increases glucose metabolism in myotubes from lean, obese and type 2 diabetic individuals.
Article in Diabetologia, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 68 citations in OpenAlex.
- A PUFA-rich diet improves fat oxidation following saturated fat-rich meal.European journal of nutrition · 2017Trial
- Energy metabolism in skeletal muscle cells from donors with different body mass index.Frontiers in physiology · 2022Article
- The Liver under the Spotlight: Bile Acids and Oxysterols as Pivotal Actors Controlling Metabolism.Cells · 2021Review
- Treatment of human skeletal muscle cells with inhibitors of diacylglycerol acyltransferases 1 and 2 to explore isozyme-specific roles on lipid metabolism.Scientific reports · 2020Article
- Morin, a novel liver X receptor α/β dual antagonist, has potent therapeutic efficacy for nonalcoholic fatty liver diseases.British journal of pharmacology · 2017Article
- Exercise in vivo marks human myotubes in vitro: Training-induced increase in lipid metabolism.PloS one · 2017Article
- LXRα fuels fatty acid-stimulated oxygen consumption in white adipocytes.Journal of lipid research · 2014Article
- LXR is a negative regulator of glucose uptake in human adipocytes.Diabetologia · 2013Article
- Danthron activates AMP-activated protein kinase and regulates lipid and glucose metabolism in vitro.Acta pharmacologica Sinica · 2013Article
- Liver X receptors and fat cell metabolism.International journal of obesity (2005) · 2012Review
- Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2012Article
- Article
- Identification of biological markers of liver X receptor (LXR) activation at the cell surface of human monocytes.PloS one · 2012Article
- Electrical pulse stimulation of cultured human skeletal muscle cells as an in vitro model of exercise.PloS one · 2012Article
- Overexpression of PGC-1α increases fatty acid oxidative capacity of human skeletal muscle cells.Biochemistry research international · 2012Article
- Metabolic switching of human myotubes is improved by n-3 fatty acids.Journal of lipid research · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aims/hypothesisLiver X receptors (LXRs) play important roles in lipid and carbohydrate metabolism. The purpose of the present study was to evaluate effects of the endogenous LXR agonist 22-R-hydroxycholesterol (22-R-HC) and its stereoisomer 22-S-hydroxycholesterol (22-S-HC), in comparison with the synthetic agonist T0901317 on lipid and glucose metabolism in human skeletal muscle cells (myotubes).
methodsMyotubes established from lean and obese control volunteers and from obese type 2 diabetic volunteers were treated with LXR ligands for 4 days. Lipid and glucose metabolisms were studied with labelled precursors, and gene expression was analysed using real-time PCR.
resultsTreatment with T0901317 increased lipogenesis (de novo lipid synthesis) and lipid accumulation in myotubes, this increase being more pronounced in myotubes from type 2 diabetic volunteers than from lean volunteers. Furthermore, 22-S-HC efficiently counteracted the T0901317-induced enhancement of lipid formation. Moreover, synthesis of diacylglycerol, cholesteryl ester and free cholesterol from acetate was reduced below baseline by 22-S-HC, whereas glucose uptake and oxidation were increased. Both 22-S-HC and 22-R-HC, in contrast to T0901317, decreased the expression of genes involved in cholesterol synthesis, whereas only 22-R-HC, like T0901317, increased the expression of the gene encoding the reverse cholesterol transporter ATP-binding cassette subfamily A1 (ABCA1). CONCLUSIONS/
interpretationT0901317-induced lipogenesis and lipid formation was more pronounced in myotubes from type 2 diabetic patients than from lean individuals. 22-S-HC counteracted these effects and reduced de novo lipogenesis below baseline, while glucose uptake and oxidation were increased.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.